Maxon One Explodes with Exciting New Features and Workflow Improvements
9.11.2022 20:00:00 EET | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced several updates to the company’s Maxon One product line. The November 2022 release features a blazingly hot new feature for Cinema 4D - Pyro. Pyro allows artists to create fire, smoke and explosions - easily simulated using GPU or CPU. Other Cinema 4D features include an integrated Redshift Camera and Radial Symmetry for modeling. Forger expands its professional modeling functions by adding Cinema 4D's advanced Symmetry capabilities. The latest release of VFX enhances Real Lens Flares with more natural elements, adding Schmutz and Diffraction effects to the optical simulation. The latest version of Trapcode offers an interactive and updated user interface for Particular's curves and color gradients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005139/en/
Maxon One Receives New Features and Improvements in November Release: Cinema 4D receives new Pyro tool, Trapcode Particular shines in an updated UI, the first full version of Real Lens Flares is released and Forger expands professional modeling capabilities. (Graphic: Business Wire)
Cinema 4D 2023.1: Cinema 4D introduces Pyro! for creating fire, smoke and explosions. Seamless integration in Cinema 4D’s Unified Simulation System, means Cloth and Soft Bodies can be set ablaze and fan the flames. A newly integrated RedShift Camera brings intuitive physical camera controls and Redshift effect settings. New Radial Symmetry modeling allows the interactive modeling of anything round by defining a number of slices and offset. And, many more workflow enhancements are included.
Forger: Forger continues to add the comprehensive modeling capabilities of Cinema 4D to iPad with the addition of Symmetry modeling, bringing desktop power and workflows to mobile flexibility.
VFX: The latest version of VFX introduces the first full version of Real Lens Flares adding Schmutz and Diffraction to make lens look grimy and add rippling effects to each lens flare reflection element. Dozens of presents as well as base lens prescriptions have also been added.
Trapcode: Trapcode 2023.1 offers a completely refreshed and upgraded user interface for the Particular curves and color gradients as well as new emitter block presets for Form behaviors and improved performance.
Capsules: Maxon continues to deliver valuable Capsule assets that subscribers can use as a creative kickstart. Artists can now easily compose a product shot with the new Backdrop Primitive, and a new Square Star Spline and FUI Ring Spline create a variety of crosshair and reticule shapes for FUI graphics.
Cineware for Unreal: An updated Cineware for Unreal integration now supports Cinema 4D 2023.1 and Unreal Engine 5.0.3. Easily import C4D files into Unreal and make changes without leaving the engine environment.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005139/en/
Contact information
Press
Chloe Larby
Grithaus Agency
chloe@grithaus.agency
+44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 15:00:00 EEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom